Havana, Apr 29.- The final results of the study confirming the effectiveness of CIMAvax-EGF in advanced lung cancer will be presented at an international workshop to be held here on May 12 and 13, specialized sources reported today.
The implementation of the vaccine -conceived by experts of the Center for Molecular Immunology (CIM-Spanish acronym)- in primary health care, the overall safety profile and follow-up experiences in other countries, will also be addressed in the V International Workshop on the topic, to be held in the Palace of Conventions.
The event, organized by CIMAB S.A., a Cuban biopharmaceutical company dedicated to the development and commercialization of drugs for the treatment of malignant tumors, will aim to discuss new indications and therapeutic combinations of the compound.
CIMAvax-EGF is the first registered therapeutic vaccine for lung cancer, considered a novel approach capable of generating the patient’s own antibodies against the epidermal growth factor (EGF).
The antibodies generated halt the proliferation of tumor cells, consequently the progression of the disease is controlled, chances of survival increase, as well as the quality of life of treated patients. (Prensa Latina)
Radio Cadena Agramonte, April 29, 2015